Acceleron Weans Itself Off VC, Continues its Roll with Pharma Partner Dollars

Acceleron has raised an additional $140 million from its pharma partners, which includes a $45 million down payment from Shire Pharma for development of muscle enhancing drugs. Acceleron’s promising clinical trial results from its ACE-031 drug and additional compounds coming from its strong platform technology has contributed to their successful fund raising campaign.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail